- Home
- RMCO vs NRXS Comparison
RMCO vs NRXS Comparison
Compare RMCO & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMCO
- NRXS
- Stock Information
- Founded
- RMCO 2021
- NRXS 2011
- Country
- RMCO United States
- NRXS United States
- Employees
- RMCO N/A
- NRXS N/A
- Industry
- RMCO Multi-Sector Companies
- NRXS
- Sector
- RMCO Miscellaneous
- NRXS
- Exchange
- RMCO Nasdaq
- NRXS Nasdaq
- Market Cap
- RMCO 14.9M
- NRXS 13.0M
- IPO Year
- RMCO N/A
- NRXS 2023
- Fundamental
- Price
- RMCO $1.28
- NRXS $2.44
- Analyst Decision
- RMCO
- NRXS Strong Buy
- Analyst Count
- RMCO 0
- NRXS 1
- Target Price
- RMCO N/A
- NRXS $7.00
- AVG Volume (30 Days)
- RMCO 18.0K
- NRXS 159.0K
- Earning Date
- RMCO 08-14-2025
- NRXS 08-08-2025
- Dividend Yield
- RMCO N/A
- NRXS N/A
- EPS Growth
- RMCO N/A
- NRXS N/A
- EPS
- RMCO N/A
- NRXS N/A
- Revenue
- RMCO $1,568,212.00
- NRXS $2,934,945.00
- Revenue This Year
- RMCO N/A
- NRXS $138,883.78
- Revenue Next Year
- RMCO N/A
- NRXS $118.59
- P/E Ratio
- RMCO N/A
- NRXS N/A
- Revenue Growth
- RMCO 204.08
- NRXS 27.52
- 52 Week Low
- RMCO $0.74
- NRXS $1.33
- 52 Week High
- RMCO $1.32
- NRXS $6.20
- Technical
- Relative Strength Index (RSI)
- RMCO 62.27
- NRXS 47.31
- Support Level
- RMCO $1.19
- NRXS $2.33
- Resistance Level
- RMCO $1.30
- NRXS $2.65
- Average True Range (ATR)
- RMCO 0.06
- NRXS 0.17
- MACD
- RMCO 0.02
- NRXS -0.01
- Stochastic Oscillator
- RMCO 80.00
- NRXS 32.14
About RMCO Royalty Management Holding Corporation
Royalty Management Holding Corp formed to invest or purchase assets that have current or near-term income to provide the company with accretive cash flow from which it can reinvest in new assets or expand cash flow from existing assets. These assets typically are natural resources assets (including real estate and mining permits), patents, intellectual property, and emerging technologies.
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).